Skip to content
Navigate to homepage - Cerba Research
Resource Library

Poster – Workflow And Troubleshooting For Performance Qualification Of Cytek Aurora Instrument In A Clinical Setting

The ability of developing high-parameter assays allows for a deeper characterization of patients’ immune subsets with limited sample availability. Spectral flow cytometry is used to assess high-parameter immune profiling in global clinical trials. To date, there are no specific guidelines for Performance Qualification (PQ) of spectral flow cytometers. Here, we describe an in-house developed workflow for performing PQ of a Cytek® Aurora instrument in a clinical laboratory.

Cerba Research US - Flow Cytometry Cytek Aurora

Cerba US Expansion Tour VF.00_04_27_19.Still010

Reach out to our experts and discover how we can help you transform research and advance health

Contact Us
Resource Library

Poster – Upscaling Of A Clinical Flow Cytometry Laboratory

As flow cytometry is one of the go-to methods for fast and in-depth monitoring of immune cell populations at single cell level, clinical laboratories are observing an increase in assay complexity and number of samples to process. To scale up our operations in a qualitative and efficient manner, several aspects of the laboratory design were improved and are discussed below.

Cerba US Expansion Tour VF.00_04_27_19.Still010

Reach out to our experts and discover how we can help you transform research and advance health

Contact Us
Resource Library

Brochure – Cerba Research Genomics Experience In Oncology

Since 1992, Cerba Research/Healthcare has pioneered the art of human genetic testing, Cerba Healthcare builds the start of the art in human genetic testing by being the first laboratory in Europe to introduce Genetic testing.

Thanks to this experience, we are able to collaborate with the life science community to provide the most suitable genomic service and enhance the power of your genetic material.

Cerba Research can work with you to select the most suitable platform and assay to reach your project expectations.

Discover all our capabilities in our latest Genomics Brochure

Cerba US Expansion Tour VF.00_04_27_19.Still010

Reach out to our experts and discover how we can help you transform research and advance health in the field of genomics.

Contact Us
Resource Library

White paper – Decoding A TCR And BCR Fingerprint – Immune Repertoire Sequencing

Welcome to our immune repertoire sequencing white paper page! We provide advanced solutions to study the diversity and specificity of immune cells in your clinical trial samples, using cutting-edge sequencing technologies and bioinformatic tools.

By analyzing the RNA sequences of the immune receptors (i.e., B-cell or T-cell receptors), we can identify and quantify the different types of immune cells present in your samples, as well as their clonal relationships and antigen recognition patterns. This information can be used to investigate immune responses to diseases, vaccines, tumors, or environmental stimuli, and to develop personalized therapies and diagnostics.

Our team of experts can guide you through the entire process, from sample preparation to data analysis and interpretation, and provide you with customized reports and visualizations.

Explore the power of immune repertoire sequencing and unlock the secrets of the immune system!

What you can find in the white papers:

  • The TCR and BCR sequencing workflow
  • Our standard report analysis
  • Cerba Research end-to-end solution sequencing service
  • Features and benefits of TCR and BCR profiling
  • And more intriguing features

Complete the form below to download the white papers!

Cerba US Expansion Tour VF.00_04_27_19.Still010

Reach out to our experts and discover how we can help you transform your research and advance health in the field of immune repertoire sequencing.

Contact Us
Resource Library

E-book – CAR+T Drug Development The Critical Role Of Flow Cytometry

Being one of the leading technologies for cellular analysis, flow cytometry generates simultaneous high-throughput enumeration and individual cell characterization data. With the breakthrough of cellular immune therapies, such as CAR+ T, flow cytometry became a critical platform, not only for clinical laboratories, but also for drug developers and manufacturers.

Flow cytometry plays a crucial role in the production process of CAR+ T cells, where it is used for assessing transduction efficiency, purity, and characterization of the CAR+ T product before infusion. After manufacturing, when CAR+ T cells are infused into the patients, flow cytometry is used again in clinical laboratories to assess CAR+ T expansion, efficiency, and persistence and to monitor minimal residual disease (MRD).

In this e-book, Ans De Beuckelaer, Regional Head Flow Cytometry EU and Rowan Claeys, Clinical Biologist at Cerba Research, dive deeper into key elements of flow cytometry:

  • The importance of flow cytometry in Car+T clinical research and its uses
  • Key aspects in developing a CAR+ T trial
  • The added value of flow cytometryin multiple myeloma, Minimal Residual Disease (MRD) assessments and multiple Myeloma phenotype
  • Car+T-cell Therapy: patient treatment, targeted antigens and solutions for MRD assessments and multiple myeloma phenotype assessment.
Cerba Research - Ebook - CAR+T Drug Development The Critical Role of Flow Cytometry
Cerba US Expansion Tour VF.00_04_27_19.Still010

Reach out to our experts and discover how we can help you transform your research in the field of flow cytometry or CAR T

Contact Us
Resource Library

Presentation – Automatization Of Immunohistochemistry Data Analysis For Protocol Validation

This presentation was given by Marie Gerus-Durand, Principal Scientist & Validation Engineer at Cerba Research Montpellier at the JMP Discovery Summit Europe.

Cerba Research is a global company providing high-quality, specialized analytical and diagnostic solutions for clinical trials. Cerba Research Montpellier develops customized immunohistochemistry protocols to detect the expression of selected targets on patients’ tissue sections.

To be used in clinical trials, these protocols must meet the regulatory agencies’ criteria to ensure that the protocol will allow consistent results on precious patients’ samples. With the diversity of parameters evaluated and the types of evaluation possible in implementing these custom protocols, automating data analysis became a need.

Thanks to various JMP® tools, we have developed an automated analysis that saves time and homogenizes protocol performance reports by including statistical and graphical data in a Dashboard. This process, submitted as JMP Add-in, has been incorporated into our user workflows, thus facilitating our procedures.

Tour our IHC Centre of Excellence in 360°

Cerba Research takes you on a 360 degree tour of their IHC Centre of Excellence lab

Reach out to our experts and discover how we can help you transform your research and advance health

Contact Us
Resource Library

Case Study – A Blood-based Biomarker Panel For Non-invasive Diagnosis Of Non-alcoholic Steatohepatitis: A Multi-centre Prospective And Validation Study

A late-stage biopharmaceutical company dedicated to metabolic and chronic liver diseases is developing an in vitro diagnostic (IVD) test for NASH at-risk patients. The test integrates four independent biomarkers – miR-34a-5p, A2M, YKL-40, and HbA1c. The output is a 0-10 score with threshold values, identifying patients with low risk or high risk of developing NASH.

The main objective of this study is to evaluate the physiological stability of these biomarkers between the fed and fasting state in patients with the target condition (NAFLD) over a 30-day period.

Discover how our team of experts helped this biopharmaceutical company to reach its goals

Cerba US Expansion Tour VF.00_04_27_19.Still010

Reach out to our experts and discover how we can help transform your research to advance health

Contact Us
Resource Library

White Paper – Nonnegotiable Central Laboratory Capabilities For I/O Clinical Trial Success

In immuno-oncology (I/O), meeting budget and timeline expectations in the journey from translational research to commercialization is a challenge. You need expert, integrated central laboratory and diagnostic solutions delivered by top scientists who will help you assess needs and generate early insights that optimize your protocol.

What else should you look for in a clinical laboratory partner? Along with access to a sizable patient database, impeccable performance across the globe, and I/O experience, three main testing capabilities are mandatory for success in this field: immunohistochemistry, flow cytometry, and next-generation sequencing.

Cerba US Expansion Tour VF.00_04_27_19.Still010

Reach out to our experts & discover how we can help you transform research and advance health

Contact Us
Resource Library

Webinar – Turning Precision Medicine Into Action In Immuno-Oncology

The challenges in immuno-oncology (I/O) drug development require deep scientific insights, generation and analysis of complex biological data, new state-of-the art technologies and both logistical & operational support across continents. The goal of immuno-oncology drug developers is to turn precision medicine into action, bringing life-changing therapies to patients.

In this webinar originally held on October 4 our experts discuss the use of Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), and Flow Cytometry (FCM) within immuno-oncology, and how they can offer the comprehensive insights required for I/O clinical trials.

Speakers

  • Jérôme Sallette, PhD, CSO Cerba Research
  • Shu Jen Chen, PhD, CSO ACT Genomics
  • Sofie Vandevyver, PhD, Head of Business Operations & Marketing Cerba Research
  • George Wei, PhD, Vice President R&D ACT Genomics
  • Renaud Burrer, PhD, Head of Histopathology Cerba Research
  • Nithianandan Selliah, PhD, Global Head Flow Cytometry Cerba Research

Resource Library

Poster – Non-Invasive Serum Lipidomic Approach To Discriminate Non-Alcoholic Steatohepatitis (NASH) In Multiethnic Patients With Type 2 Diabetes Mellitus

Despite the growing prevalence of NASH, there are currently no approved treatments for the disease beyond liver transplant. The constellation of risk factors for NASH has generated a multitude of targets and there is an obvious need to bring promising treatments through clinical trials and to patients quickly. 

Cerba US Expansion Tour VF.00_04_27_19.Still010

Reach out to our experts and discover how we can help you advance your research

Contact Us